Free Trial
NASDAQ:FTXH

First Trust Nasdaq Pharmaceuticals ETF (FTXH) Price, Holdings, & News

$26.98 +0.24 (+0.90%)
(As of 12/20/2024 05:16 PM ET)

About First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH)

Key Stats

Today's Range
$26.89
$27.05
50-Day Range
$26.74
$29.16
52-Week Range
$25.73
$29.72
Volume
2,078 shs
Average Volume
5,018 shs
Market Capitalization
$16.19 million
Assets Under Management
$14.73 million
Dividend Yield
2.11%
Net Expense Ratio
0.60%
Aggregate Rating
Moderate Buy

ETF Overview

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.

First Trust Nasdaq Pharmaceuticals ETF Expenses

TypeFTXHHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFs
Management Fee0.60%0.57%0.55%0.50%0.52%
Other Expenses0.00%0.30%0.49%0.41%0.53%
Total Expense0.60%0.70%0.71%0.64%0.71%
Fee Waiver0.00%-0.45%-0.51%-0.31%-0.56%
Net Expense0.60%0.61%0.61%0.57%0.59%
Receive FTXH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for First Trust Nasdaq Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter.

FTXH ETF News Headlines

Cackling Kamala hates this company
Do you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution.
Solid Q4 Earnings Fail to Impress Pharma ETFs
See More Headlines

FTXH ETF - Frequently Asked Questions

First Trust Nasdaq Pharmaceuticals ETF's stock was trading at $26.62 on January 1st, 2024. Since then, FTXH stock has increased by 1.4% and is now trading at $26.98.
View the best growth stocks for 2024 here
.

Top institutional investors of First Trust Nasdaq Pharmaceuticals ETF include NBC Securities Inc. (0.92%).

Shares of FTXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that First Trust Nasdaq Pharmaceuticals ETF investors own include Digirad (DRAD), RAIT Financial Trust (RAS), Cummins (CMI), Auxly Cannabis Group (CBWTF), Blueknight Energy Partners (BKEP), Biocept (BIOC) and BioCorRx (BICX).

Fund Details

Issuer
First Trust
Fund Name
First Trust Nasdaq Pharmaceuticals ETF
Tax Classification
Regulated Investment Company
Current Symbol
NASDAQ:FTXH
Inception Date
9/20/2016
Fund Manager
Daniel Lindquist, Jon Erickson, David McGarel, Roger Testin, Stan Ueland, Chris Peterson, Erik Russo
Web
N/A

Fund Focus

Asset Class
Equity
Benchmark
Nasdaq US Smart Pharmaceuticals Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
51

Fund Statistics

Assets Under Management
$14.73 million
Average Daily Volume
$2,148.20
Discount/Premium
0.04%

Administrator, Advisor and Custodian

Administrator
The Bank of New York Mellon Corporation
Advisor
First Trust Advisors L.P.
Custodian
The Bank of New York Mellon Corporation
Distributor
First Trust Portfolios L.P.
Transfer Agent
The Bank of New York Mellon Corporation
Trustee
N/A
Lead Market Maker
Old Mission

Options

Optionable
N/A
Short Interest
200 shs

Miscellaneous

Beta
0.70
Creation Unit
50,000
Creation Fee
$500.00
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Top 10 FTXH Holdings

FTXH Sector Exposure

FTXH Industry Exposure


This page (NASDAQ:FTXH) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners